Erasca, Inc. Marketable Securities (Current)
Erasca, Inc. (ERAS) had Marketable Securities (Current) of $226.20 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-11
- 2026-06-30: Marketable Securities, Current $226.20M.
- 2026-03-31: Marketable Securities, Current $196.53M.
- 2025-12-31: Marketable Securities, Current $202.27M.
- 2025-09-30: Marketable Securities, Current $218.17M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $226.20M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $196.53M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $202.27M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $218.17M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $234.52M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $234.10M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $230.57M 10-K · filed 2026-03-12 |
| 2024-09-30 | $250.03M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $235.61M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $220.96M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $219.28M 10-K · filed 2025-03-20 |
| 2023-09-30 | $183.81M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $178.46M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $116.98M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $151.40M 10-K · filed 2024-03-27 |
| 2022-09-30 | $136.67M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $73.47M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $59.19M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $53.99M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |